The present invention relates to methods and compositions for the reduction of
xenotransplantation rejection. Specifically, the present invention relates, first, to transgenic cells, tissues, organs and animals containing transgenic
nucleic acid molecules that direct the expression of
gene products, including, but not limited to enzymes, capable of modifying, either directly or indirectly,
cell surface
carbohydrate epitopes such that the
carbohydrate epitopes are no longer recognized by natural human antibodies or by the
human cell-mediated immune response, thereby reducing the human
immune system response elicited by the presence of such
carbohydrate epitopes. In a preferred embodiment, the transgenic cells, tissues, organs and animals express
nucleic acid molecules encoding functional recombinant alpha-Galactosidase A (alphaGalA)
enzyme which modifies the carbohydrate
epitope Galalpha(1,3)Gal. In a more preferred embodiment, the transgenic cells, tissues, organs and animals expressing the functional recombinant alphaGalA are transgenic pig cells, organs, tissues and / or animals. Second, the present invention relates to methods for
xenotransplantation comprising introducing the transgenic cells, tissues and / or organs into human recipients so that a lower level of hyperacute rejection (HAR) is observed in the human recipients relative to the level of HAR observed in human recipients having received non-transgenic cells, tissues and / or organs.